Adagene Inc. (ADAG) on Tuesday said that it received directions from the U.S. Food and Drug Administration on further clinical development of its investigational drug Muzastotug in combination with ...

Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific T Cell Engager, from Genrix Bio for Development in Autoimmune Diseases Provided by GlobeNewswire Jun ...